GHK (Glycine-Histidine-Lysine Tripeptide) vs Oxytocin
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHK (Glycine-Histidine-Lysine Tripeptide)
The free tripeptide component of GHK-Cu before copper complexation. GHK naturally occurs in human plasma, saliva, and urine and promotes wound healing, collagen synthesis, and anti-inflammatory activity. While it readily chelates copper to form GHK-Cu in vivo, research distinguishes the independent effects of free GHK from the copper-complexed form on gene expression and tissue remodeling.
Full profileOxytocin
Endogenous 9-amino acid neuropeptide produced in the hypothalamus with roles in social bonding, trust, and childbirth. Research applications span wound healing, anti-inflammatory effects, sexual function, anxiety reduction, and autonomic nervous system regulation. Intranasal administration crosses the blood-brain barrier and is the primary research route for behavioral and neurological applications.
Full profile| GHK (Glycine-Histidine-Lysine Tripeptide) | Oxytocin | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | GHK tripeptide, Gly-His-Lys, copper chelating tripeptide, GHK free tripeptide | OT, Pitocin, Syntocinon, trust hormone, bonding peptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 0.5mg–2mg mg, Daily or every other day (topical or SC) | 10–20IU–100–160IU IU, Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols |
| Administration | Subcutaneous injection, Topical (cream/serum) | Intranasal spray, Subcutaneous injection, Intravenous (clinical) |
| Key side effects | Minimal reported side effects, Mild injection site irritation, Rare topical sensitization, No significant systemic effects at research doses | Nausea, Headache, Transient hypotension, Hyponatremia (high IV doses — water retention effect) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: GHK (Glycine-Histidine-Lysine Tripeptide) — Subcutaneous injection, Topical (cream/serum); Oxytocin — Intranasal spray, Subcutaneous injection, Intravenous (clinical).
- Dosing units differ: GHK (Glycine-Histidine-Lysine Tripeptide) is dosed in mg, Oxytocin in IU — they operate at different scales.
- Frequency: GHK (Glycine-Histidine-Lysine Tripeptide) is typically Daily or every other day (topical or SC); Oxytocin is Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols.
How each works
GHK (Glycine-Histidine-Lysine Tripeptide)
Free GHK directly upregulates collagen, elastin, and laminin synthesis in fibroblasts through TGF-β pathway activation and metalloproteinase modulation. Loren Pickart's decades of research identified GHK as a potent tissue remodeling signal whose plasma concentrations decline with age. At physiologic concentrations, GHK resets approximately 31% of dysregulated gene expression associated with aging back toward a younger phenotype.
Oxytocin
Oxytocin binds oxytocin receptors (OTR) throughout the brain and periphery, producing prosocial, anxiolytic, and anti-inflammatory effects. The landmark 2005 Kosfeld et al. Nature study demonstrated that intranasal oxytocin increased trust in humans in economic game paradigms. Peripheral effects include acceleration of wound healing, modulation of inflammatory cytokines, and parasympathetic nervous system activation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.